Drugs.com - Clinical Trials

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer

Redwood City, Calif., June 3, 2025 – Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food and...

Jun 3, 2025 - 22:55
 0
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
Redwood City, Calif., June 3, 2025 – Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food and...
Read More

Tags:

Previous Article

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal wort...

Next Article

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

Related Posts

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designa...

Jun 5, 2025  0

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Linvoseltamab in Combination with Carfilzomib or Bortez...

May 25, 2025  0

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025  0